In particular, EGFRGScore ~ 0.8 reveals those well-known mutations with clinical significance related to drug response (L858R) while EGFRGScore ~ 0.4 corresponds to mutations residues that are not located in the protein kinase domain and that are less frequently found in cancer patients but that may have a deleterious functional effect (i.e. EGFR p.L62R). Here, WEE1 is linked to cancer.